FTRE vs TMO vs EVO Stock Comparison

Fortrea Holdings, Thermo Fisher Scientific and Evotec SE Prices as of Nov 13, 2026 Peers: Industry group
1 more company in this comparison (IQV) Create a free account to keep reading and compare up to 10 companies.
FTRE Fortrea Holdings Inc.
$20.20 -5.3% 1M +97.7% 1Y
Market cap
$1.89B
P/E
–
Revenue (TTM)
$2.67B
Div. yield
–
Contract Research Healthcare
2 wins
EVO Evotec SE
$1.58 +11.3% 1M -50.2% 1Y
Market cap
$559.37M
P/E
–
Revenue (TTM)
—
Div. yield
–
Contract Research Healthcare

Head to Head

10 decided of 12

Thermo Fisher Scientific leads on 8 of the 12 questions below (Thermo Fisher Scientific 8, Fortrea Holdings 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionFTRETMOEVOLeader
Larger companyMarket capitalisation $1.89B $255.60B $559.37M TMO
Cheaper on earningsLower P/E, profitable companies only -27.5x 36.1x — –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 24.6x 27.0x — FTRE
Faster revenue growthRevenue growth, trailing twelve months -2.6% +8.3% — TMO
More profitableNet margin, trailing twelve months -2.6% 14.9% — TMO
Better return on capitalReturn on invested capital 0.8% 8.0% — TMO
Less leveragedLower net debt / EBITDA 9.2x 3.1x — TMO
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +97.7% +20.7% -50.2% FTRE
Better 5-year returnAnnualised price return, 5 years — +2.0%/yr -41.8%/yr TMO
Less volatileAnnualised volatility, 1 year 67.9% 30.7% 56.8% TMO
Higher overall scoreMean of the five percentile scores vs peers 58/100 60/100 — TMO

Percentile Scorecard

FTRETMOEVO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisFTRETMOEVO
Valuation 90 #2 of 11 62 #94 of 243 –
Growth 90 #2 of 11 41 #136 of 228 –
Profitability 50 #6 of 11 82 #40 of 222 –
Financial Health 0 #13 of 13 31 #172 of 248 83 #3 of 13
Shareholder Returns – 82 #29 of 158 –
Overall 58 60 –
  • FTRE ranked among 13 companies in Pharma Services
  • TMO ranked among 252 companies in Medical Devices and Diagnostics
  • EVO ranked among 13 companies in Pharma Services

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodFTRETMOEVOSPY
1 month -5.3%+4.0%+11.3% -2.0%
3 months +16.0%+19.1%-19.4% -2.8%
6 months +47.9%+59.7%-41.5% +2.0%
Year to date +17.1%+20.8%-48.7% +10.6%
1 year +97.7%+20.7%-50.2% +12.2%
3 years -37.8%+52.5%-84.3% +68.1%
3 years, per year -14.7%+15.1%-46.1% +18.9%
5 years —+10.2%-93.3% +61.4%
5 years, per year —+2.0%-41.8% +10.1%
10 years —+362.9%— +248.5%
10 years, per year —+16.6%— +13.3%

Risk

MeasureFTRETMOEVOSPY
Volatility, 1Y 67.9%30.7%56.8% 13.6%
Downside volatility, 1Y 64.3%29.2%61.3% 13.9%
Beta vs S&P 500, 1Y 1.680.711.14 1.00
Return / volatility, 1Y 1.440.67-0.88 0.90
Max drawdown, 5Y -89.9%-41.5%-94.6% -25.4%
From 52-week high -21.9%-3.0%-59.2% -3.2%
52-week high $25.88$721.63$3.87 $779.14
52-week low $8.87$438.34$1.35 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleFTRETMOEVO
P/E now vs peer median -28.1xmedian 34.7x 36.6xmedian 26.5x —median 34.7x
P/S now vs peer median 0.7xmedian 2.5x 5.5xmedian 2.7x —median 2.5x
EV/EBITDA now vs peer median 30.5xmedian 29.1x 25.5xmedian 18.4x —median 29.1x
P/FCF now vs peer median 11.5xmedian 21.0x 34.2xmedian 25.4x —median 21.0x
P/B now vs peer median 3.7xmedian 1.6x 4.7xmedian 2.5x 0.8xmedian 1.6x
PEG now vs peer median 0.46median 1.98 4.84median 0.98 —median 1.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsFTRETMOEVO
Revenue $2.67B $47.35B –
Gross profit $533.40M $19.45B –
Operating income $12.80M $8.47B –
Net income -$68.70M $7.09B –
Free cash flow $169.00M $7.60B –
R&D – $1.40B –
EPS (diluted) $-0.68 $19.06 –
Cash & equivalents $220.60M $5.46B $339.10M
Total debt $1.06B $41.37B $546.42M
Shares (diluted) 101.20M 371.00M –
Enterprise value $1.18B $232.12B -$1.20B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricFTRETMOEVO
P/E -28.1x 36.6x –
P/FCF 11.5x 34.2x –
P/Operating cash flow 9.7x 27.8x –
P/S 0.7x 5.5x –
P/B 3.7x 4.7x 0.8x
P/Tangible book -49.1x 7.1x 0.8x
EV/EBITDA 30.5x 25.5x –
EV/EBIT 218.2x 34.8x –
EV/Revenue 1.0x 6.2x –
EV/FCF 16.5x 38.8x –
EV/Operating cash flow 13.8x 31.6x –
PEG (3Y EPS CAGR) 0.46 4.84 –

Growth

14 metrics
MetricFTRETMOEVO
Revenue growth (1Y) -2.6% 8.3% –
Revenue CAGR (3Y) 0.4% 2.9% –
Gross profit growth (1Y) 2.4% 7.8% –
Gross profit CAGR (3Y) -8.5% 4.0% –
Operating income growth (1Y) 101.5% 12.8% –
Operating income CAGR (3Y) -43.3% 7.2% –
Net income growth (1Y) 93.0% 7.9% –
Net income CAGR (3Y) -47.8% 6.2% –
EPS growth (1Y) 93.7% 9.7% –
EPS CAGR (3Y) -60.7% 7.6% –
Operating cash flow growth (1Y) 589.8% 21.9% –
Operating cash flow CAGR (3Y) 76.5% 4.5% –
Free cash flow growth (1Y) 347.8% 24.3% –
Free cash flow CAGR (3Y) 148.9% 5.1% –

Profitability

14 metrics
MetricFTRETMOEVO
Gross margin 20.0% 41.1% –
EBITDA margin 3.4% 24.4% –
Operating margin 0.5% 17.9% –
Pretax margin -2.0% 16.7% –
Net margin -2.6% 14.9% –
FCF margin 6.3% 16.0% –
Operating cash flow margin 7.6% 19.7% –
Return on equity -13.0% 13.2% –
Return on assets -2.5% 6.2% –
Return on invested capital 0.8% 8.0% –
Return on capital employed 0.7% 8.5% –
Asset turnover 1.0x 0.4x –
Cash conversion (OCF / net income) -2.9x 1.3x –
Stock comp / revenue 1.9% 0.7% –

Financial Health

11 metrics
MetricFTRETMOEVO
Debt / assets 38.9% 36.2% 32.0%
Debt / equity 2.0x 0.8x 0.8x
Net debt / EBITDA 9.2x 3.1x –
Debt / FCF 6.3x 5.4x –
Liabilities / assets 80.6% 52.1% 57.4%
Equity / assets 19.4% 47.9% 42.6%
Interest coverage – 12.0x –
Current ratio 1.0x 1.8x 2.3x
Quick ratio 0.9x 1.2x 1.6x
Cash ratio 0.2x 0.4x 1.1x
Altman Z-score 0.78 4.18 –

Shareholder Returns

7 metrics
MetricFTRETMOEVO
Dividend yield – 0.3% –
Net buyback yield – 1.6% –
Shareholder yield – 1.8% 0.0%
Payout ratio (earnings) – 9.5% –
Payout ratio (FCF) – 8.9% –
Dividend growth (1Y) – 8.0% –
Dividend CAGR (3Y) – 10.1% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusFTRETMOEVO
Forward P/E 24.6xFY2026 27.0xFY2026 –
EPS, next fiscal year $0.82FY2026 $25.92FY2026 $-0.75FY2026
EPS growth, next FY +90.7%FY2026 +13.3%FY2026 –
EPS growth, the year after +19.5% +2.2% –
Revenue, next fiscal year $2.79BFY2026 $50.12BFY2026 $694.45MFY2026
Revenue growth, next FY +2.5%FY2026 +12.5%FY2026 -24.7%FY2026
Revenue growth, the year after -3.8% -2.7% +13.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersFTRETMOEVO
Held by institutions 100.0% 90.2% 0.9%
Institutions holding 331 2,627 35
Change in shares held, QoQ -0.2% +0.8% -60.2%
Institutions buying 139 1,145 18
Institutions selling 108 1,145 7
Buyers to sellers 1.29 1.00 2.57

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

FTRETMOEVO
FTRE 1.00 0.54 0.31
TMO 0.54 1.00 0.26
EVO 0.31 0.26 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, FTRE, TMO and EVO?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Fortrea Holdings (FTRE) $1.89B, Thermo Fisher Scientific (TMO) $255.60B, Evotec SE (EVO) $559.37M.

Which company is growing faster?

Thermo Fisher Scientific (TMO) grew revenue fastest over the trailing twelve months: Fortrea Holdings (FTRE) -2.6%, Thermo Fisher Scientific (TMO) +8.3%.

Which company is more profitable?

Thermo Fisher Scientific (TMO) has the highest net margin (Fortrea Holdings (FTRE) -2.6%, Thermo Fisher Scientific (TMO) 14.9%). On return on invested capital, Thermo Fisher Scientific (TMO) leads (Fortrea Holdings (FTRE) 0.8%, Thermo Fisher Scientific (TMO) 8.0%).

Which stock has performed better?

Over the past year Fortrea Holdings (FTRE) returned the most: Fortrea Holdings (FTRE) +97.7%, Thermo Fisher Scientific (TMO) +20.7%, Evotec SE (EVO) -50.2%. Over five years, Thermo Fisher Scientific (TMO) compounded fastest (Thermo Fisher Scientific (TMO) +2.0%/yr, Evotec SE (EVO) -41.8%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Fortrea Holdings (FTRE) 0.00%, Thermo Fisher Scientific (TMO) 0.00%, Evotec SE (EVO) 0.00%. Fortrea Holdings (FTRE) and Evotec SE (EVO) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Thermo Fisher Scientific (TMO) has been the steadiest (Fortrea Holdings (FTRE) 67.9%, Thermo Fisher Scientific (TMO) 30.7%, Evotec SE (EVO) 56.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, FTRE, TMO and EVO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Thermo Fisher Scientific (TMO) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.